Alzheimer's disease is the most common form of dementia and includes cognitive, personality, and behavioral changes. The 2024 report from the Alzheimer's Association estimated that 6.9 million adults >65 years in the US are currently living with Alzheimer's disease. Modeling studies predict that this number will double by 2050, and associated healthcare costs will reach $1 trillion. In June 2021, regulatory approval of aducanumab, a humanized recombinant monoclonal antibody to amyloid ß, initially raised expectations for improved disease-modifying therapy. However, in February 2024, production of aducanumab and a post-marketing clinical trial ceased in the US due to the costs and limitations of aducanumab therapy. In March 2024, biobank data identified significant modifiable risk factors for Alzheimer's disease, including diabetes mellitus, exposure to nitrogen dioxide (a proxy for air pollution), and the frequency of alcohol intake. Therefore, modification of identifiable risk factors, combined with testing for disease-susceptibility genes, could be the most effective approach to reduce the incidence. This article aims to review the current status of disease-modifying therapies and prevention of Alzheimer's disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097689 | PMC |
| http://dx.doi.org/10.12659/MSM.945091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mortality Rates and Forensic Causes after Hip Fracture: A Retrospective Observational Study.
Arch Bone Jt Surg
January 2024
Özel Medicabil Hastanesi, Bursa.
Objectives: Despite the widely recognised high mortality rate among patients with hip fracture, the variation in death rates by gender and cause has been less explored. This study aimed to investigate mortality rates and causes of death in patients who underwent hip fracture surgery, and to compare them with those of the general population. A secondary objective was to compare the results of Internal Fixation versus Arthroplasty in these patients.
View Article and Find Full Text PDFAssessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in individuals with dementia.
Front Neurol
January 2025
Department of Neurology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, Jiangsu, China.
Background: Autonomic dysfunction plays an essential role in dementia, however, it is not known whether electrocardiogram autonomic dysfunction-related indicators are associated with the severity of dementia. In this study, we attempted to investigate whether these indicators are correlated in patients with vascular dementia and Alzheimer's disease compared with normal health individuals. For this purpose, we measured and analyzed the predictive value of heart rate deceleration capacity (DC), heart rate deceleration runs (DRs), heart rate acceleration capacity (AC) along with the plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2).
View Article and Find Full Text PDFClinical characteristics and biomarker profile in early- and late-onset Alzheimer's disease: the Shanghai Memory Study.
Brain Commun
January 2025
Institute and Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Early-onset Alzheimer's disease constitutes ∼5-10% of Alzheimer's disease. Its clinical characteristics and biomarker profiles are not well documented. To compare the characteristics covering clinical, neuropsychological and biomarker profiles between patients with early- and late-onset Alzheimer's disease, we enrolled 203 patients (late-onset Alzheimer's disease = 99; early-onset Alzheimer's disease = 104) from a Chinese hospital-based cohort, the Shanghai Memory Study.
View Article and Find Full Text PDFExploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.
Heliyon
January 2025
Laboratory of Neurochemistry and Behaviour, Experimental Neurobiology Unit, University of Antwerp, Belgium.
People with Down Syndrome (DS) are at high risk of developing Alzheimer's disease dementia (AD) and cerebral amyloid angiopathy, which is a critical factor contributing to dementia in sporadic AD. Predicting and monitoring the decline and onset of dementia is a diagnostic challenge and of essence in daily care and support for people with DS. In this literature scoping review, we first summarize the different blood-based biomarkers for AD in DS.
View Article and Find Full Text PDFRoles of endoplasmic reticulum stress and activating transcription factors in Alzheimer's disease and Parkinson's disease.
Tzu Chi Med J
August 2024
Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan.
Endoplasmic reticulum (ER) is a crucial organelle associated with cellular homeostasis. Accumulation of improperly folded proteins results in ER stress, accompanied by the reaction involving triggering unfolded protein response (UPR). The UPR is mediated through ER membrane-associated sensors, such as protein kinase-like ER kinase (PERK), inositol-requiring transmembrane kinase/endoribonuclease 1α, and activating transcription factor 6 (ATF6).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!